Related Experiment Video
Updated: Jul 15, 2026

An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes
Published on: April 26, 2019
Immune crosstalk in metabolic dysfunction-associated steatotic liver disease: interactions between innate and
Xiangqiong Li1,2,3, Kunnu Jin1,2,3, Jindong Fang1,2,3
1Collge of Basic Medical Sciences, Yunnan University of Chinese Medicine, Kunming, Yunnan, China.
Abstract:
Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as the leading chronic liver disorder worldwide. Its pathological progression typically begins with hepatic steatosis, advances to metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, and in some cases culminates in hepatocellular carcinoma (HCC). This continuum is influenced not only by metabolic disturbances but also by coordinated local and systemic inflammatory and immune responses. This article systematically summarizes the inflammatory mechanisms underlying MASLD/MASH progression, highlighting their origin in the dynamic crosstalk between innate and adaptive immune compartments. Such interactions involve multiple immune cell subsets, including macrophages, T lymphocytes, and B lymphocytes, and are governed by intricate molecular regulatory pathways. Furthermore, this review explores how these interconnected processes amplify hepatic inflammation and fibrogenesis and discusses potential therapeutic approaches to modulate key nodes within immune signaling networks.
Related Concept Videos
Cirrhosis II: Pathophysiology
Inflammatory Bowel Disease III: Crohn's Disease
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Cell-mediated Immune Responses
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test